CART cells are prone to Fas- and DR5-mediated cell death. Issue 1 (13th July 2018)

• Record Type: Journal Article
• Authors: Tschumi, Benjamin O.; Dumauthioz, Nina; Marti, Bastien; Zhang, Lianjun; Schneider, Pascal; Mach, Jean-Pierre; Romero, Pedro; Donda, Alena
• Is Part Of: Journal for immunotherapy of cancer. Volume 6:Issue 1(2018)
• Publication Date: 2018-07-13
• Subjects: CAR T cells -- CD8 T lymphocytes -- Fas -- FasL -- Annexin V -- Listeria monocytogenes -- HER2 -- 4-1BB -- CD28 -- CD3ζ; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/s40425-018-0385-z
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Adoptive transfer of T cells transduced with Chimeric Antigen Receptors (CAR) are now FDA-approved for the treatment of B-cell malignancies. Yet, the functionality of the endogenous TCR in CART cells has not been fully assessed. Here, we demonstrate that CART cells progressively upregulate Fas, FasL, DR5 and TRAIL, which result in their programmed cell death, independently of antigen-mediated TCR or CAR activation. CART cell apoptosis occurs even when the CAR contains a single (co-)activatory domain such as CD3ζ, CD28 or 4-1BB. Importantly, the dominant role of the Fas and DR5 pathways in CART cell apoptosis is demonstrated by the significant rescue of CART cells upon in vivo blockade by combined Fas-Fc and DR5-Fc recombinant proteins. These observations are of crucial importance for the long-term persistence of CART cells and for the development of new applications including the combined TCR and CAR activation against solid tumors.